Heather Wade
Family · Mechanicsville, VANPI 1023552742
Payments from drug & device makers
Across 363 payments — averaging $18.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Novo Nordisk$909
- Lilly USA, LLC$638
- Zealand Pharma US, Inc.$483
- Abbott$465
- Insulet Corporation$402
- plus $3K from 34 others
What the payments were for
- Food & beverage$6,806100%
- Education$320%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 63 | $1,195 |
| Novo Nordisk | 57 | $909 |
| Lilly USA, LLC | 40 | $638 |
| Zealand Pharma US, Inc. | 19 | $483 |
| Abbott | 31 | $465 |
| Insulet Corporation | 11 | $402 |
| AbbVie | 11 | $240 |
| Medtronic | 13 | $229 |
| Sanofi-aventis U.S. LLC | 9 | $205 |
| Amgen | 10 | $190 |
| Antares Pharma, Inc. | 9 | $172 |
| Amneal Pharmaceuticals LLC | 9 | $150 |
| Lifescan, Inc. | 6 | $133 |
| Boehringer Ingelheim | 7 | $113 |
| Amarin Pharma, Inc. | 6 | $111 |
| Bayer | 6 | $108 |
| Radius Health, Inc. | 4 | $100 |
| Tolmar, Inc. | 5 | $92 |
| Mannkind Corporation | 4 | $88 |
| Cequr Corporation | 3 | $83 |
| Intuity Medical Inc | 3 | $77 |
| Xeris Pharmaceuticals, Inc. | 4 | $74 |
| Tandem Diabetes Care, Inc. | 4 | $66 |
| Clarus Therapeutics Inc. | 7 | $65 |
| Astellas Pharma US Inc | 3 | $63 |
| Dexcom, Inc. | 2 | $48 |
| Novartis | 2 | $46 |
| Regeneron Healthcare Solutions, Inc. | 2 | $38 |
| Merck | 2 | $32 |
| BETA Bionics, Inc. | 1 | $26 |
| Gilead | 1 | $26 |
| Ascendis Pharma Endocrinology Inc | 1 | $24 |
| Eisai Inc. | 1 | $23 |
| Azurity Pharmaceuticals, Inc. | 1 | $21 |
| Halozyme Inc | 1 | $21 |
| Recordati_rare_diseases_inc. | 1 | $21 |
| Endo Pharmaceuticals Inc. | 1 | $19 |
| IBSA Pharma Inc. | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Acella Pharmaceuticals, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,838 in reported general payments places this provider in the 95th percentile of 4,332 family providers in Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 210 | $301,364 |
| TrulicityDulaglutide | 78 | $118,529 |
| FarxigaDapagliflozin Propanediol | 119 | $107,384 |
| MounjaroTirzepatide | 66 | $100,655 |
| JardianceEmpagliflozin | 99 | $92,462 |
| Xigduo XrDapaglifloz Propaned/Metformin | 66 | $57,071 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 43 | $41,297 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 35 | $34,075 |
| Tresiba Flextouch U-100Insulin Degludec | 49 | $27,878 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 26 | $27,407 |
| JanuviaSitagliptin Phosphate | 35 | $25,464 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 27 | $25,090 |
| RybelsusSemaglutide | 16 | $19,092 |
| VascepaIcosapent Ethyl | 36 | $18,093 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 26 | $17,012 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $909 | $320,456226 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Insulin Lispro | $638 | $228,944192 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Synjardy, Tradjenta | $113 | $154,190188 claims |
| AstraZenecaFarxiga | $1,195 | $107,384119 claims |
| MerckJanumet Xr, Januvia | $32 | $66,76278 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $205 | $10,44619 claims |
| AbbVieSynthroid | $240 | $7,396115 claims |
| Amneal Pharmaceuticals LLCUnithroid, Levothyroxine Sodium | $150 | $5,379293 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,332 family providers in Virginia.
Other family in Mechanicsville
- Andrea CottonVirginia Beach$696K
- Susan MooreWytheville$438K
- Ellen WermterCharlottesville$251K
- Dana StallingsFranklin$225K
- Jocelyn BrackettHerndon$199K
- Hochong Smith GillesRichmond$131K
- Sean OlaughlinMidlothian$110K
- Adam MedlinHampton$67K
- Casey SharpDanville$63K
- Norman JacobowitzManassas$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.